|
Nitrosamine impurities in human medicines/ European Medicines Regulatory Network
|
|
0
|
359
|
July 29, 2025
|
|
Nitrosamine Control Strategies: From Risk Identification to Implementation
|
|
3
|
453
|
July 24, 2025
|
|
N-nitrosamine risk assessment in pharmaceuticals: Where are we from a regulatory point of view in 2025?
|
|
0
|
407
|
July 24, 2025
|
|
Highlights from the 13th meeting of the Nitrosamine Implementation Oversight Group (NIOG)
|
|
7
|
568
|
July 22, 2025
|
|
Analytical Procedures and Validation_Specificity parameter requirment
|
|
9
|
708
|
July 9, 2025
|
|
Addendum to ICH M7 on Risk Assessment and Control of N-Nitrosamine Impurities
|
|
8
|
2511
|
July 3, 2025
|
|
🚨 FDA deadline update
|
|
14
|
1372
|
August 7, 2025
|
|
Cleaning procedure for glassware used in the analysis of nitrosamines for LC-MS/MS
|
|
2
|
453
|
May 23, 2025
|
|
Nitrosamine Mitigation: A Path to Regulatory Compliance
|
|
1
|
490
|
May 11, 2025
|
|
Nitrosourea, aromatic n-nitroso copmounds
|
|
2
|
263
|
May 2, 2025
|
|
Autonomous CPCA Web-based calculator FREE
|
|
33
|
7067
|
April 30, 2025
|
|
Annex 2 WHO good practice considerations for the prevention and control of nitrosamines in pharmaceutical products
|
|
0
|
480
|
April 16, 2025
|
|
Nitrosamines Safety Operational Expert Group
|
|
0
|
166
|
April 16, 2025
|
|
Clobam Nitrosamine Impurity
|
|
0
|
189
|
April 8, 2025
|
|
Acceptance criteria for Nitrosamines Method Validation
|
|
3
|
518
|
March 14, 2025
|
|
CDER Drug Safety Priorities Fiscal Year 2023
|
|
2
|
707
|
February 27, 2025
|
|
Adjustment of the MDD with CYP inducers?
|
|
2
|
184
|
February 13, 2025
|
|
EMA nitrosamine Q&A Appendix 1 rev.7 published on Dec 13, 2024
|
|
8
|
2774
|
January 27, 2025
|
|
ICH M7 & Nitrosamines Impurities -Updates
|
|
15
|
5271
|
January 20, 2025
|
|
Control Strategy - Testing Frequency
|
|
10
|
524
|
January 20, 2025
|
|
🇲🇽 Mexico Q&A Live session streaming
|
|
7
|
773
|
January 6, 2025
|
|
Critical comparison of BMD and TD50 methods for the calculation of acceptable intakes for N-nitroso compounds -Pub
|
|
0
|
325
|
January 3, 2025
|
|
CHPA's response to the Control of Nitrosamine Impurities in Human Drugs rev.2
|
|
1
|
438
|
January 2, 2025
|
|
AI for pharmaceutical legislation, including nitrosamines
|
|
4
|
461
|
December 30, 2024
|
|
WHO good manufacturing practices considerations for the prevention and control of nitrosamine contamination in pharmaceutical products
|
|
4
|
1235
|
December 21, 2024
|
|
Methylene Blue NDSRI
|
|
6
|
653
|
November 22, 2024
|
|
New EMA Nitrosamine impurities page
|
|
0
|
474
|
November 21, 2024
|
|
Terbinafine Nitrosamines
|
|
3
|
354
|
November 14, 2024
|
|
NDSRI limit for N-nitroso Ciprofloxacin
|
|
2
|
399
|
November 1, 2024
|
|
FDA Statement on Ritonavir and NITMA
|
|
1
|
447
|
October 29, 2024
|